Related Experiment Video
Updated: Aug 17, 2026

08:34
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
10.8K
Novartis's Kymriah: Harnessing Immune System Comes With Worry About Reining in Costs
Abstract:
FDA approval of the CAR T-cell therapy for leukemia could usher in an era of genetically engineered, individually tailored immunotherapies. But tap those brakes. Long-term results are in short supply-and there's that $475,000 price tag. Or is it a $750,000 price tag?
Keywords:
Tomorrow’s Medicine
